Copy
EuropaBio's Weekly Newsletter
EuropaBio's 20 year anniversary: weekly spotlight on our members

Royal DSM is a global science-based company active in health, nutrition and materials. We connect our unique competences in life sciences and materials sciences to create sustainable value for all stakeholders. Based on a deep understanding of global trends that drive societies, markets and consumers, DSM creates innovative solutions in e.g. food & dietary supplements, animal nutrition & health, medical devices, paints, automotive, renewable energy and bio-based materials. DSM is convinced of and actively promotes the benefits of biotechnology as a key enabler of the bioeconomy, hence the sustainable use of renewable raw materials and the reduction of required raw materials, energy and waste. Learn more

Bioeconomy is worth €1.27 trillion and 7 million jobs

Biobased industries play a significant role in the European production and employment context, concludes a new report quantifying the economic potential of bioeconomy. Germany comes first with a production worth €343 billion, followed by France, Italy, Spain and the UK. A global look shows that worldwide exports of products related to bioeconomy amounted, in 2014, to 2,396 billion US dollars, or 12.6% of the world trade, a share which showed a considerable growth on the 9.8% of 2007. Read more
 

A Japanese hub that has fostered innovation for decades

In tourist guides and airline posters, Kyoto is pitched as the purest wellspring of traditional Japan: a kimono-scape of wood, lacquer and manicured stone gardens. Behind all that is a hub of engineering, technology and biotech that has led Japan’s start-up sector for more than half a century. Read more in The Financial Times

Agricultural biotech

The EU legislation on agricultural biotechnology is hopelessly warped. These contortions by lawmakers are aimed at identifying a (pseudo) category of products to be regulated separately, subjected to sectarian bureaucratic regulations: pointless tests, interminable analyses and needlessly repeated studies. Read more 

Healthcare biotech

The European Union  Council of Ministers approved a detailed policy plan aiming at promoting the use of personalised medicines across the EU. Notably, the plan tells the European Commission and other organisations to investigate using Big Data to make these pharmaceuticals work better. Read more

Industrial biotech

Applications to be part of the new European Union Bioeconomy stakeholder Panel are open until February 5. The panel will work on bioeconomy policy challenges, including on synergies with related policy areas like food and nutrition security, and will contribute to the review of the EU Bioeconomy Strategy. Apply here
Key dates to keep in mind
https://www.facebook.com/pages/EuropaBio/74765722914
https://www.linkedin.com/company/europabio
http://www.europabio.org/
Copyright © *2015* *EuropaBio*, All rights reserved.

Our mailing address is:
Avenue de l'Armée 6
B-1040 Brussels

unsubscribe from this list